Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Cancer
- Drugs
- Medical
- Drug Discovery
- Supply
- Tissue
- Therapeutic
- Biotechnology
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 266679
This research and collaboration agreement is to analyze and assess the potential clinical utility of certain compounds owned or licensed by Licensee.
Product means a preparation containing a Verified Compound having at least one indication for which Success has been predicted by Licensor under the Program.
·
Our Personalized Oncology Solutions (“POS) business which provides services to physicians and patients looking for information to help guide the development of a personalized treatment plans.
·
Our Translational Oncology Solutions (“TOS) business, which provides services to pharmaceutical and biotech companies seeking personalized approaches to drug development that will lower the cost and increase the speed of developing new drugs and increasing the adoption of existing drugs.
Our technology platform consists of processes, physical tumors and information that we use to personalize the development and use of oncology drugs. Our process technology involves the
·
implantation of human tumor fragments in immune compromised mice;
·
expansion of the original human tumor into a larger colony of mice through the passage of the tumor to subsequent generations of mice;
·
treatment of the implanted mice with oncology drugs;
·
measurement of tumor growth inhibition in treated mice relative to a control group of mice to determine the response of the tumor to the drug.
Our process is used for our POS business to test numerous drugs or drug combinations against a single patient’s tumor to determine which therapy results in the most efficacious response from the tumor.
IPSCIO Record ID: 276094
The patient data and molecular information associated with these tumors, are referred to as “TumorGrafts†or “Patient Derived XenoGrafts†or “PDX Modelsâ€.
Our clinical trial simulation platform consists of processes, physical tumors, and information that we use to personalize the development and use of oncology drugs.
Patient derived xenografts are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse.
PDX models mimic the unique make-up of an individual’s tumor and may help guide the most effective treatment.
IPSCIO Record ID: 415
A patent application has been filed for the technology entitled Combination Immunogene Therapy, United States Patent Application No. 09/826,025. The standard approach in utilizing gene therapy to combat cancer has been to attempt to replace defective genes in cancer cells, which has proven to be impractical because of the number of genes involved. The combination gene therapy technology invented by Dr. Chang uses GM-CSF (a granulocyte macrophage colony stimulating factor) and B7-2 (a T-cell co-stimulating factor) to both build the body’s immune system and destroy cancer cells. The treatment involves injecting the patient with two genes in one virus carrying a combination of B7-2 and GM-CSF. Our technology, which shows potential for fighting cancer by enhancing one’s immune system and thereby increasing the number of cells that naturally destroy cancer, has proven effective in eradicating experimental human brain tumors implanted in mice and has undergone Phase 1 clinical trials in Canada.
IPSCIO Record ID: 67226
